Panelist: Jawad Hasan
Jawad Hasan is an accomplished biopharmaceutical executive with over 17 years of experience in global drug safety, pharmacovigilance, and medical affairs. He currently serves as Therapeutic Area Head, Global Patient Safety – Metabolics at AstraZeneca, a role he has held since July 2021. Based in Boston, Massachusetts, he leads safety strategy and benefit-risk evaluation for AstraZeneca’s metabolic disease portfolio.
Prior to AstraZeneca, Jawad spent over five years at Alexion Pharmaceuticals, rising to the role of Executive Medical Director, where he led global safety oversight for rare disease products and contributed to regulatory submissions and safety governance. His earlier roles include senior leadership positions at Biogen, Vertex Pharmaceuticals, and Sentrx, where he developed and implemented global safety strategies during pivotal stages of drug development and commercialization.
Jawad brings deep expertise in medical safety, risk management, and cross-functional leadership across multiple therapeutic areas, including neurology, rare diseases, and metabolics. Throughout his career, he has been consistently recognized for his collaborative approach and strategic contributions to clinical development and patient safety.
Jawad is also endorsed for his skills in medical affairs and has held key roles across various leading biotechnology and pharmaceutical companies in the Greater Boston Area.